Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised double blind study of subcutaneous icatibant vs oral tranexamic acid in hereditary angioedema attacks
2004-001540-71Phase 3Completed
- Sponsor
- Jerini AG
- Start
- Dec 2004
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of icatibant in hereditary angioedema (HAE) (2 arms), sponsored by Jerini AG. Primary endpoint: Onset of relief of symptoms. Started Dec 2004; status: completed.
02
Drugs
icatibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2004-001540-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001540-71.